enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Lenalidomide - Wikipedia

    en.wikipedia.org/wiki/Lenalidomide

    Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]

  3. Tafasitamab - Wikipedia

    en.wikipedia.org/wiki/Tafasitamab

    Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). [5] Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. [7]

  4. Revlimid Gains, Celgene Loses - AOL

    www.aol.com/news/2013-06-05-celgene-gains-new...

    Good newsThe U.S. Food and Drug Administration approved Revlimid as. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ...

  5. Cereblon E3 ligase modulator - Wikipedia

    en.wikipedia.org/wiki/Cereblon_E3_ligase_modulator

    The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.

  6. Celgene and Pharmacyclics Bring Big Change to Mantle Cell ...

    www.aol.com/2013/12/13/celgene-and-pharmacyclics...

    Patients with mantle cell lymphoma got new hope thanks to newly approved treatments in 2013. That's good news for the 2,800 U.S. patients with MCL, a hard-to-treat disease with a significant need ...

  7. Can This Celgene Drug Defy the Patent Cliff? - AOL

    www.aol.com/news/2013-02-11-a-wile-e-coyote-kind...

    For premium support please call: 800-290-4726 more ways to reach us

  8. Ixazomib - Wikipedia

    en.wikipedia.org/wiki/Ixazomib

    In this study, ixazomib increased the median time of progression-free survival from 14.7 months (in the placebo+lenalidomide+dexamethasone study arm including 362 people) to 20.6 months (under ixazomib+lenalidomide+dexamethasone, 360 people), which was a statistically significant effect (p = 0.012). 11.7% of patients in the ixazomib group had a ...

  9. These 2 Stocks Just Declared Dividend Raises That Kick In ...

    www.aol.com/finance/2-stocks-just-declared...

    A pair of blockbuster cancer drugs, Revlimid and Abraxane, began falling off the patent cliff in 2022, and not coincidentally, the company's annual sales dipped in both that year and in 2023.